製品番号: HY-N6042

Copy Link Print Information

Hernandezine

(別名: Hernandesine)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Hernandezine (Hernandesine) is isolated from Thalictrum glandulosissimum.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.55%
CAS 番号: 6681-13-6
分子式: C₃₉H₄₄N₂O₇
分子量:652.78

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Hernandezine 構造式

CAS 番号: 6681-13-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Hernandezine (Hernandesine) is isolated from Thalictrum glandulosissimum^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	7.2 μM Compound: HER	Cytotoxicity against human A-375 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35544345]
A549	IC₅₀	7.59 μM Compound: HER	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
B16	IC₅₀	5.9 μM Compound: HER	Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 35544345]
HEK293	IC₅₀	0.07 μM Compound: Hernandezine	Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM) Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM)	[PMID: 27504669]
HEK293	IC₅₀	1.21 nM Compound: Hernandezine	Potentiation of mitoxantrone-induced cytotoxicity against HEK293 cells assessed as mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 1 +/- 0.19 nM) Potentiation of mitoxantrone-induced cytotoxicity against HEK293 cells assessed as mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 1 +/- 0.19 nM)	[PMID: 27504669]
HEK293	IC₅₀	109 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	25.27 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	3.85 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	300 nM Compound: Hernandezine	Inhibition of human ABCB1-mediated efflux transfected in HEK293 cells assessed as accumulation of fluorescent dye by calcein-AM dye based FACS analysis Inhibition of human ABCB1-mediated efflux transfected in HEK293 cells assessed as accumulation of fluorescent dye by calcein-AM dye based FACS analysis	[PMID: 27504669]
HEK293	IC₅₀	38.32 μM Compound: Hernandezine	Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM) Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM)	[PMID: 27504669]
HEK293	IC₅₀	43.93 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	5.63 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	6.81 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	6.99 nM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM) Potentiation of doxorubicin-induced cytotoxicity against HEK293 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by CCK8 assay (Rvb = 5.28 +/- 0.74 nM)	[PMID: 27504669]
HEK293	IC₅₀	75.77 nM Compound: Hernandezine	Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM) Inhibition of human ABCB1 transfected in HEK293 cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by CCK8 assay (Rvb = 504.65 +/- 44.94 nM)	[PMID: 27504669]
HEK293	IC₅₀	85.08 nM Compound: Hernandezine	Inhibition of human ABCG2 R482 mutant transfected in HEK293 cells assessed as potentiation of mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 107.40 +/- 13.93 nM) Inhibition of human ABCG2 R482 mutant transfected in HEK293 cells assessed as potentiation of mitoxantrone-induced cytotoxicity by measuring mitoxantrone IC50 at 500 nM after 72 hrs by CCK8 assay (Rvb = 107.40 +/- 13.93 nM)	[PMID: 27504669]
Hep 3B2	IC₅₀	6.71 μM Compound: HER	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
HepG2	IC₅₀	7.42 μM Compound: HER	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
KB 3-1	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.13 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.14 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.15 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM) Potentiation of doxorubicin-induced cytotoxicity against human KB-3-1 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.15 +/- 0.04 uM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.59 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.62 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.63 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	0.63 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM) Potentiation of vincristine-induced cytotoxicity against human KB-3-1 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.78 +/- 0.27 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.15 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 100 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 100 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.29 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 500 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 500 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.33 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 200 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 200 nM by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
KB 3-1	IC₅₀	9.77 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.81 +/- 3.80 nM) Potentiation of colchicine-induced cytotoxicity against human KB-3-1 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.81 +/- 3.80 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	0.23 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	0.55 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	1.31 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	1009.5 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	115.02 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	2.81 μM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of doxorubicin-induced cytotoxicity by measuring doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 5.54 +/- 0.60 uM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	223.72 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	2660.5 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	3220.21 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	571.36 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	79.31 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of colchicine-induced cytotoxicity by measuring colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 1607.50 +/- 497.42 nM)	[PMID: 27504669]
NCI/ADR-RES	IC₅₀	969.58 nM Compound: Hernandezine	Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM) Inhibition of human ABCB1 expressed in NCI-ADR-RES cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 3714.80 +/- 383.58 nM)	[PMID: 27504669]
NCI-H1299	IC₅₀	6.74 μM Compound: HER	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability by MTT assay	[PMID: 35544345]
OVCAR-8	IC₅₀	0.1 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.11 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	0.12 μM Compound: Hernandezine	Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM) Potentiation of doxorubicin-induced cytotoxicity against human OVCAR8 cells assessed as doxorubicin IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 0.12 +/- 0.03 uM)	[PMID: 27504669]
OVCAR-8	IC₅₀	20.45 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	22.11 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	22.75 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	24.53 nM Compound: Hernandezine	Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM) Potentiation of colchicine-induced cytotoxicity against human OVCAR8 cells assessed as colchicine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 27.26 +/- 9.96 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	4.94 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 200 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.02 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 500 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.14 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 100 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]
OVCAR-8	IC₅₀	6.38 nM Compound: Hernandezine	Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM) Potentiation of vincristine-induced cytotoxicity against human OVCAR8 cells assessed as vincristine IC50 at 50 nM after 72 hrs by MTT assay (Rvb = 8.53 +/- 1.95 nM)	[PMID: 27504669]

化学情報

CAS 番号 6681-13-6
性状 Solid
分子量 652.78
分子式 C₃₉H₄₄N₂O₇
Color White to off-white
SMILES

COC1=C(O2)C3=C(CCN(C)[C@@]3([H])CC4=CC=C(OC)C(OC5=CC=C(C=C5)C[C@@]6([H])C7=C(CCN6C)C=C(OC)C2=C7)=C4)C(OC)=C1OC
別名

Hernandesine
Structure Classification
- Quinones
- Anthraquinones
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Phytomedicine

Hernandezine acts as a CDK4 suppressor inhibiting tumor growth by the CDK4/PKM2/NRF2 axis in colon cancer. [Abstract]

2024 Aug:131:155775. PMID: 38838401

溶剤 & 溶解度

体外:

DMSO : 6.25 mg/mL (9.57 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5319 mL

7.6595 mL

15.3191 mL

5 mM

0.3064 mL

1.5319 mL

3.0638 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.62 mg/mL (0.95 mM); Clear solution

This protocol yields a clear solution of ≥ 0.62 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.62 mg/mL (0.95 mM); Clear solution

This protocol yields a clear solution of ≥ 0.62 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.2 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ropivia J, et al. Isoquinolines from the roots of Thalictrum flavum L. and their evaluation as antiparasitic compounds. Molecules. 2010 Sep 16;15(9):6476-84. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5319 mL	7.6595 mL	15.3191 mL	38.2977 mL
DMSO	5 mM	0.3064 mL	1.5319 mL	3.0638 mL	7.6595 mL

Keywords

Hernandezine

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Hernandezine

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Quinones Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Natural Product Library

Anti-Cancer Compound Library

MedChemExpress（MCE）の使用を引用している文献 Hernandezine

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Hernandezine

Traditional Chinese Medicine Active Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Quinones Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Natural Product Library

Anti-Cancer Compound Library

MedChemExpress（MCE）の使用を引用している文献 Hernandezine

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Hernandezine 関連分類

HY-N6042 関連分類